Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hengrui Reports PD-1 Combo Therapy Effective in Global Trial for Liver Cancer

publication date: May 13, 2022

Jiangsu Hengrui Medicine announced that a combination of its PD-1 and VEGFR inhibitors met its efficacy endpoints in patients with newly diagnosed liver cancer, outperforming Bayer’s Nexavar. The global Phase III trial tested the combination therapy for overall survival. Hengrui has already filed for China approval of the combination and plans to seek US approval as well. Hengrui and its US partner Elevar started US trials for the combination in 2019, so they have efficacy data in US patients. The lack of that data caused the US to reject two China-developed immunotherapies recently. More details....

Stock Symbol: (SHA: 600275)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital